Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Methodological standard

Draft standard: freeze–thaw and in-use stability assessment of reconstituted peptide solutions

Consultation on the draft standard for freeze–thaw and in-use stability assessment of reconstituted peptide solutions. The draft specifies the cycling regime, the hold conditions and the stability-indicating determinations required, and records that a…

Document identifier
CEI-CP-023
Series
Public comment period
Version
1.0
Published
26 Jun 2026
Last reviewed
26 Jun 2026
Next review
26 Jun 2027
Identifier
10.71829/cei.cp.23
Certainty
Not rated
Cycle
2026 Q2
Window
13 Apr 2026 – 25 May 2026
Status
Closed
Submissions
15

§1Consultation and window

§1.1Window

Opened
13 April 2026
Closed
25 May 2026
Duration
42 days
Status
Closed — the disposition is published
Document under consultation
Standard CEI-MS-21
Submissions received
15

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the freeze–thaw cycling regime representative of the handling a reconstituted solution actually receives?
  2. Should the standard require an aggregation determination alongside a purity determination, given that aggregated species may not be recovered from a reverse-phase column?
  3. Does the standard state clearly enough that an in-use stability result applies to the container, closure and diluent tested and to no other combination?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The standard was amended before ratification. An aggregation determination by size-exclusion chromatography is now required alongside the purity determination, and the dependence of an in-use result on the specific container and closure system is stated in the scope rather than in the limitations.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.